AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30871431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative RCT approaches (adaptive designs, pragmatic trials, realist RCTs)
Number of subjects: 0
Study 30871431 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on structural inequalities
Number of subjects: 0
Study 28454809 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime presentation
Number of subjects: 1161
Study 28454809 — intervention group
Group type: COMPARATOR
Intervention: Nighttime presentation
Number of subjects: 1161
Study 26475845 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible dialysis fluid (low in glucose degradation products)
Number of subjects: 18
Study 26475845 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis fluids
Number of subjects: 18
Study 24332587 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraperiosteal injection of methylprednisolone
Number of subjects: 44
Study 24332587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablets of methylprednisolone
Number of subjects: 44
Study 24332587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) injection of methylprednisolone
Number of subjects: 44
Study 24332587 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroids)
Number of subjects: 44
Study 21947409 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack weighing 15 kg
Number of subjects: 7
Study 21947409 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack weighing 25 kg
Number of subjects: 7
Study 21947409 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack weighing 35 kg
Number of subjects: 7
Study 21947409 — intervention group
Group type: COMPARATOR
Intervention: No backpack (NP)
Number of subjects: 7
Study 21947409 — intervention group
Group type: EXPERIMENTAL
Intervention: Un-weighted backpack (NW)
Number of subjects: 7
Study 19211720 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 kcal/min lipid (L3)
Number of subjects: 10
Study 19211720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 kcal/min lipid and 1 kcal/min maltodextrin (L2/CHO1)
Number of subjects: 10
Study 19211720 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 kcal/min lipid and 2 kcal/min maltodextrin (L1/CHO2)
Number of subjects: 10
Study 17308271 — intervention group
Group type: EXPERIMENTAL
Intervention: DN-101 (45 microg orally 1 day before docetaxel)
Number of subjects: 250
Study 17308271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 250
Study 17308271 — intervention group
Group type: EXPERIMENTAL
Intervention: DN-101
Number of subjects: 250
Study 17308271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 12532367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-designed discharge-planning project (intervention)
Number of subjects: 283
Study 12532367 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study 11093967 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (60 g ethanol) with a standard dinner
Number of subjects: 0
Study 8899140 — intervention group
Group type: EXPERIMENTAL
Intervention: Rape Supportive Cognitions (RSC) intervention
Number of subjects: 74
Study 8899140 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim Empathy/Outcome Expectancies (VE/OE) intervention
Number of subjects: 74
Study 8899140 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 74
Study 1815002 — intervention group
Group type: EXPERIMENTAL
Intervention: +0.50 D x 090
Number of subjects: 8
Study 1815002 — intervention group
Group type: COMPARATOR
Intervention: +0.12 DS
Number of subjects: 8
Study 6356605 — intervention group
Group type: COMPARATOR
Intervention: Verbascan (10 mg three times daily)
Number of subjects: 50
Study 31995686 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional management
Number of subjects: 316
Study 31995686 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 316
Study 31995686 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional management (sensitivity analysis)
Number of subjects: 316
Study 31995686 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (sensitivity analysis)
Number of subjects: 316
Study 30649492 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual traction
Number of subjects: 20
Study 30649492 — intervention group
Group type: COMPARATOR
Intervention: Touch
Number of subjects: 20
Study 28573777 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐05231023
Number of subjects: 107
Study 25669832 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Number of subjects: 80
Study 25669832 — intervention group
Group type: COMPARATOR
Intervention: Sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Number of subjects: 80
Study 22691724 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 54
Study 22691724 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 54
Study 21811060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (120 ml)
Number of subjects: 20
Study 21811060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21811060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 20
Study 21811060 — intervention group
Group type: COMPARATOR
Intervention: Pomegranate juice vs Placebo
Number of subjects: 20
Study 19549035 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (RF) ablation catheter (CRF)
Number of subjects: 30
Study 19549035 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigated RF tip catheter (IRF)
Number of subjects: 30
Study 19549035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon catheter (CB)
Number of subjects: 30
Study 16796705 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg single dose)
Number of subjects: 12
Study 17301436 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (8-week program)
Number of subjects: 36
Study 17301436 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 36
Study 10321615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Q aerosol foam skin protectant
Number of subjects: 20
Study 10321615 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 8550681 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin, 300 international units per kilogram of body weight per day
Number of subjects: 200
Study 8550681 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin, 100 international units per kilogram of body weight per day
Number of subjects: 200
Study 8550681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1650750 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 U ACTH
Number of subjects: 12
Study 1650750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms CRH
Number of subjects: 12
Study 1650750 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 6761096 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy (SPV) plus ulcerectomy
Number of subjects: 41
Study 6761096 — intervention group
Group type: COMPARATOR
Intervention: Billroth I gastrectomy
Number of subjects: 41
Study 31471967 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Source Data Verification (SDV)
Number of subjects: 126
Study 31471967 — intervention group
Group type: COMPARATOR
Intervention: Full Source Data Verification (SDV)
Number of subjects: 126
Study 29365196 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal dexamethasone
Number of subjects: 310
Study 29365196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antenatal dexamethasone)
Number of subjects: 310
Study 26953770 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Rectal Channel Catheter (BRCC)
Number of subjects: 54
Study 26953770 — intervention group
Group type: COMPARATOR
Intervention: MRI without BRCC
Number of subjects: 54
Study 24530403 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 with low-dose (0.25mg/dose) CPG 7909
Number of subjects: 0
Study 24530403 — intervention group
Group type: COMPARATOR
Intervention: AVA (Anthrax Vaccine Adsorbed, no CPG 7909)
Number of subjects: 0
Study 24530403 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909
Number of subjects: 0
Study 24530403 — intervention group
Group type: COMPARATOR
Intervention: AVA
Number of subjects: 0
Study 22659714 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (30 mg)
Number of subjects: 9
Study 22659714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20412605 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient supplementation (20 mg Fe and 400 microg folic acid)
Number of subjects: 402
Study 20412605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 18603822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for 12 months
Number of subjects: 84
Study 18603822 — intervention group
Group type: COMPARATOR
Intervention: Non-acarbose group (control)
Number of subjects: 84
Study 18603822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose group (subgroup analysis)
Number of subjects: 84
Study 18603822 — intervention group
Group type: COMPARATOR
Intervention: Non-acarbose group (subgroup analysis)
Number of subjects: 84
Study 15823212 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 6 million units (6-MU) thrice weekly for 24 weeks
Number of subjects: 214
Study 15823212 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 3 million units (3-MU) thrice weekly for 24 weeks
Number of subjects: 214
Study 15823212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 3-MU and 6-MU regimens
Number of subjects: 214
Study 15823212 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-MU regimen
Number of subjects: 214
Study 15823212 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cirrhotic patients
Number of subjects: 214
Study 15823212 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 214
Study 12377843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled flunisolide via metered‐dose inhaler (250 micro g per activation) eight puffs bid
Number of subjects: 40
Study 12377843 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids alone
Number of subjects: 40
Study 12377843 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 10357386 — intervention group
Group type: EXPERIMENTAL
Intervention: ddC/ZDV (zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Number of subjects: 993
Study 10357386 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV/ZDV (saquinavir 600 mg and zidovudine 200 mg every 8 h)
Number of subjects: 993
Study 10357386 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV/ddC/ZDV (saquinavir 600 mg, zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Number of subjects: 993
Study 10357386 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 993
Study 7584529 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms ovine CRH administered intravenously as a bolus every hour from 0.00 hrs. to 6.00 hrs.
Number of subjects: 14
Study 7584529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1962062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubidecarenone (CoQ10) for 6 months
Number of subjects: 44
Study 1962062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubidecarenone (CoQ10) for 3 months
Number of subjects: 44
Study 1962062 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 44
Study 31490257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus dose followed by a 2 mg/kg/h continuous infusion during the intraoperative period, continued for 1 hour postsurgery)
Number of subjects: 132
Study 31490257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 132
Study 31490257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 132
Study 30670507 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐guided WorkPlan workbook with fortnightly telephone support calls
Number of subjects: 68
Study 30670507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study 27012824 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade III central PA mobilisation performed for 3 minutes at the level of the seventh thoracic vertebra (T7)
Number of subjects: 34
Study 27012824 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (less than grade I central PA mobilisation performed for 3 minutes at T7)
Number of subjects: 34
Study 27012824 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and placebo)
Number of subjects: 34
Study 24610631 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iloprost (30 ng/kg/min)
Number of subjects: 22
Study 24610631 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose iloprost (50 ng/kg/min)
Number of subjects: 22
Study 24610631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 23152362 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone
Number of subjects: 1195
Study 23152362 — intervention group
Group type: COMPARATOR
Intervention: Placebo and prednisone
Number of subjects: 1195
Study 21448165 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus IL‐2 (400 mg twice daily + 4.5 MIU five times per week for 6 in every 8 weeks)
Number of subjects: 128
Study 21448165 — intervention group
Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 128
Study 21448165 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus IL‐2 (initial higher dose)
Number of subjects: 128
Study 21448165 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus IL‐2
Number of subjects: 128
Study 19958856 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective intra-aortic balloon pump (IABP) insertion before high-risk PCI
Number of subjects: 300
Study 19958856 — intervention group
Group type: COMPARATOR
Intervention: No planned IABP insertion
Number of subjects: 300
Study 17479921 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessing similar abstract representations of traits
Number of subjects: 0
Study 17479921 — intervention group
Group type: COMPARATOR
Intervention: Accessing irrelevant abstract representations of traits
Number of subjects: 0
Study 17479921 — intervention group
Group type: COMPARATOR
Intervention: Reading a nonword prime
Number of subjects: 0
Study 17479921 — intervention group
Group type: COMPARATOR
Intervention: Accessing knowledge of one's mother
Number of subjects: 0
Study 17479921 — intervention group
Group type: COMPARATOR
Intervention: Accessing semantic knowledge
Number of subjects: 0
Study 15208494 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (400 MBq)
Number of subjects: 201
Study 11479653 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cellulite product containing retinol, caffeine, and ruscogenine
Number of subjects: 46
Study 11479653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9494430 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-cooled jacket with inlet water temperature maintained at 10-12 degrees C and flow rates of 2.6 +/- 0.3, 4.3 +/- 0.3, and 5.1 +/- 0.3 l/h.
Number of subjects: 4
Study 9494430 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-cooled jacket
Number of subjects: 4
Study 7527462 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2
Number of subjects: 40
Study 7527462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma 2000
Number of subjects: 40
Study 7527462 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 40
Study 7527462 — intervention group
Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 40
Study 2847522 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (1.25 or 5.0 mg)
Number of subjects: 65
Study 2847522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 65
Study 2847522 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 or 80 mg)
Number of subjects: 65
Study 30866895 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised texting intervention (CRA summary letter + 24 weekly personalised text messages)
Number of subjects: 171
Study 30866895 — intervention group
Group type: COMPARATOR
Intervention: Non-personalised texting intervention (non-personalised letter + 24 weekly non-personalised text messages)
Number of subjects: 171
Study 30866895 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised texting intervention
Number of subjects: 171
Study 30866895 — intervention group
Group type: COMPARATOR
Intervention: Non-personalised texting intervention
Number of subjects: 171
Study 28337893 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic treatment (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo‐oligosaccharides) as adjunctive therapy
Number of subjects: 93
Study 28337893 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological treatment (nasal corticosteroid, oral antihistamine, and isotonic saline)
Number of subjects: 93
Study 26183306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric nutrition
Number of subjects: 146
Study 26183306 — intervention group
Group type: COMPARATOR
Intervention: Family managed nutrition
Number of subjects: 146
Study 23269991 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-RFA
Number of subjects: 189
Study 23269991 — intervention group
Group type: COMPARATOR
Intervention: RFA
Number of subjects: 189
Study 21029137 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-by-point technique
Number of subjects: 66
Study 21029137 — intervention group
Group type: COMPARATOR
Intervention: Catheter dragging technique
Number of subjects: 66
Study 18300365 — intervention group
Group type: EXPERIMENTAL
Intervention: ARVs with hydroxyurea
Number of subjects: 59
Study 18300365 — intervention group
Group type: COMPARATOR
Intervention: ARVs without hydroxyurea
Number of subjects: 59
Study 17004898 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Greek Mediterranean diet for 28 days
Number of subjects: 0
Study 17004898 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (subgroup B)
Number of subjects: 0
Study 14580632 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple reminder letter
Number of subjects: 1614
Study 14580632 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month tailored stepped intervention
Number of subjects: 1614
Study 14580632 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-month tailored stepped intervention
Number of subjects: 1614
Study 14580632 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-choice of one of the above three strategies
Number of subjects: 1614
Study 10779420 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus injection of deferoxamine
Number of subjects: 27
Study 10779420 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous continuous infusion of deferoxamine
Number of subjects: 27
Study 10779420 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term efficacy of bolus injection
Number of subjects: 27
Study 10779420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection
Number of subjects: 27
Study 8776690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmocare (high-fat formula)
Number of subjects: 0
Study 8776690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure Plus (high-carbohydrate formula)
Number of subjects: 0
Study 8776690 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC high carbohydrate formula
Number of subjects: 0
Study 8776690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free Scandishake
Number of subjects: 0
Study 1594552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal lipase
Number of subjects: 10
Study 1594552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1594552 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon (conventional pancreatin microsphere)
Number of subjects: 10
Study 1594552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrex M (newer microsphere preparation)
Number of subjects: 10
Study 3976336 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 15
Study 3976336 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.01 mg/kg, i.m.)
Number of subjects: 15
Study 3976336 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study 31347692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60 mg Fe/kg)
Number of subjects: 810
Study 31347692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60, 80 mg Fe/kg)
Number of subjects: 810
Study 31347692 — intervention group
Group type: COMPARATOR
Intervention: Fe‐Gly (40 mg Fe/kg)
Number of subjects: 810
Study 31347692 — intervention group
Group type: COMPARATOR
Intervention: Control (FeSO4, 60 mg Fe/kg)
Number of subjects: 810
Study 30413216 — intervention group
Group type: EXPERIMENTAL
Intervention: Art Therapy (AT)
Number of subjects: 68
Study 30413216 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Reminiscence Activity (MRA)
Number of subjects: 68
Study 30413216 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care without any intervention)
Number of subjects: 68
Study 28531643 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS (lipid-based nutrient supplements)
Number of subjects: 130
Study 28531643 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS-VM (lipid-based nutrient supplements with vitamins and minerals)
Number of subjects: 130
Study 28531643 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS-VM
Number of subjects: 130
Study 28531643 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS
Number of subjects: 130
Study 24695878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic cervical paramidline interlaminar epidural steroid injection (ESI)
Number of subjects: 143